Titan Pharmaceuticals (NASDAQ:TTNP) is a very interesting investment opportunity. Coming off of the bad news of an FDA Complete Response Letter regarding its lead drug compound Probuphine, the company once again looks like a rather attractive buy opportunity. It is in the beginning of conducting a clinical trial that should set the stage for FDA approval, and could be a possible takeover target should the company successfully obtain FDA approval. These events should be very lucrative for Titan shareholders and makes it appear as though Titan is largely undervalued given its long term growth potential. The purpose of this article is to discuss the current developments and potential for Titan's pipeline, and then to develop a fair value...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|